Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 12, 2020

SELL
$11.92 - $15.87 $1.08 Million - $1.43 Million
-90,405 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$7.53 - $14.93 $680,749 - $1.35 Million
90,405 New
90,405 $1.32 Million

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $823M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Partners Group Holding Ag Portfolio

Follow Partners Group Holding Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Partners Group Holding Ag, based on Form 13F filings with the SEC.

News

Stay updated on Partners Group Holding Ag with notifications on news.